Skip to main content
  1. Home
    /
  2. IPO
    /
  3. Rubicon Research IPO
Rubicon Research IPO
103.62xsubscribed

Rubicon Research IPO

Pharmaceuticals & Drugs
listed
₹13,830Min. investment

Rubicon Research Limited IPO Details

SectorPharmaceuticals & Drugs
Price range₹461 – ₹485
IPO type
Regular
Lot size30 shares
Issue size₹1,377Cr
Red Herring Prospectus
Read
Market cap
₹7,987CrLower than sector avg
RevenueApr 2024 - Mar 2025
₹1,284CrLower than sector avg
Growth rate3Y CAGR
80.65%

Rubicon Research IPO Subscription Status

Date
QIB
NII
Retail
Total
09-Oct-25
0.26 times (X)
0.46 times (X)
1.38 times (X)
0.52 times (X)
10-Oct-25
2.0X
1.8X
3.98X
2.37X
13-Oct-25
74.99X
95.07X
34.6X
103.62X

As on 09-Oct-25, 5:30 PM

Rubicon Research IPO Timeline

  1. Pre-apply
    8 Oct 2025
  2. Bid start
    9 Oct 2025
  3. Bid end
    13 Oct 2025
  4. Allotment
    14 Oct 2025
  5. Release of funds
    15 Oct 2025
  6. Demat transfer
    15 Oct 2025
  7. Listing
    16 Oct 2025

About Rubicon Research Limited

Rubicon Research Limited is a pharmaceutical formulations company dedicated to the development, manufacturing, and marketing of speciality and generic prescription medicines for regulated markets, with an emphasis on the United States.
Incorporated in 1999 as a contract formulation developer, and has developed over the years into an integrated player with capabilities across research, manufacturing, and commercialisation. It is the sole Indian pharmaceutical company with all attention concentrated in regulated markets, and more than 98% of its revenue has been sourced from the US in FY25.
Rubicon has showcased outstanding growth momentum, emerging as the fastest-growing Indian pharma formulations player between FY23 and FY25 with a revenue CAGR of 75.89%, almost 7 times greater than the peer average. As of June 2025, the company had 72 active ANDAs and 9 NDAs approved by the USFDA and a US market commercialisation rate of 86.4%, one of the highest in its category. It was one of the top 12 Indian firms in cumulative ANDA approvals in FY25.
The company’s portfolio of 66 commercialised products in the US caters to therapy areas of CNS (46.13%), CVS (38.48%), and Analgesics/Pain Management (24.10%) as of June 2025 revenue. Interestingly, nine of these have a market share of over 25% by value in the US market. Rubicon has also established a strong pipeline, with 17 new products awaiting USFDA approval and 63 candidates in development, allowing for a steady pipeline of launches.
As of June 2025, the company had 16 speciality products. Flagship brands sold through its US-based subsidiary Validus Pharmaceuticals include Equetro® and Raldesy®, the latter being the first-ever oral liquid form of Trazodone Hydrochloride to be approved by the USFDA.
Its innovation-driven edge is supported by two USFDA-inspected R&D centres (India and Canada) employing 170 scientists, and three USFDA-approved manufacturing facilities across Maharashtra and Madhya Pradesh, India. The company also owns nine proprietary drug delivery technologies and 10 patents across India and the US. Rubicon Research's manufacturing strength enables cost efficiency as Indian production costs are 30–40% lower than in the US, while maintaining stringent global quality standards.
Rubicon markets products through its wholly owned subsidiaries AdvaGen Pharma (non-branded generics) and Validus Pharmaceuticals (branded prescription products). AdvaGen can distribute products in 49 states of the US, serving wholesalers, group purchasing organisations, and national chain pharmacies. As of June 2025, the company marketed over 350 SKUs to 96 customers, including all three major US wholesalers.
The US market comprised 46.9% of the world's prescription pharmaceuticals market in 2024 and is expected to remain over 45% up to 2029, and is expected to grow at a CAGR of 7.5% from FY25 to FY30, with CNS and CVS medicines contributing 14.7% and 12.2% of this revenue, respectively. The firm is well-poised to capitalise on this growth potential through its market share of more than 25% in the US market and revenue focus on CNS and CVS drugs.
The company plans to continue to develop and market its pipeline of speciality products in central nervous system (CNS) and Cardiovascular (CVS) therapy classes with branded products promoted by Validus. It further plans to leverage its US approvals and development efforts in similarly regulated geographies like the UK, Canada, Australia, and South Africa.
Now, Rubicon Research Ltd is launching its initial public offering (IPO), which consists of a fresh issue of ₹500 crore and an offer for sale of ₹877.50 crore. The total issue size of the IPO is ₹1377.50 crore. Its shares will be listed on the NSE and BSE.

Rubicon Research Limited IPO Analysis

IPO REVIEW

Rubicon Research IPO | Analysis Video

Should you apply?

Watch our analysts break down the Rubicon Research Limited IPO — business model, financials, valuation and key risks — to help you decide whether to apply. The video covers the IPO price band, important dates, and what the subscription numbers mean for retail investors.

Checklist

Quality analysis
Revenue growth
Company valuation
Earnings expansion
Risk analysis
Debt to Equity ratio
Promoter holdings
Shares pledged
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Strength and Weakness

Leading pharmaceutical company

Between FY23 and FY25, the company was the fastest-growing Indian pharmaceutical company, with a total revenue CAGR of 75.89%, which was over seven times higher than the average. The company is the only Indian pharmaceutical player fully focused on regulated markets, with 99.50% of revenue from the US in Q1FY26. Its strong presence has translated into more than 25% market share in the US (by value) for nine products in FY25 compared to only two products in FY23.

Data-driven product selection framework

The company leverages a robust, ROI-centric, data-driven framework for product selection that helps withstand pricing pressures in the US generics market. While the overall US generics industry witnessed a 5.2% price erosion between FY22 and FY25, the company achieved an 8.0% average per unit price growth during the same period. With a strong commercialisation rate of 86.4% of approved products as of June 2025 in the US market, the framework ensures early identification of commercially viable opportunities.

Strong R&D capabilities

The company’s R&D strength is backed by 170 scientists across facilities in India and Canada, focusing on formulations and complex dosage forms. It invested ₹36.74 crore in R&D in FY2025 (10.42% of revenue), maintaining a steady allocation to innovation. These FDA-inspected facilities support the development of high-value products such as nasal sprays, inhalation therapies, and speciality drugs, with 72 active ANDAs and 9 NDAs as of June 2025.

Robust sales and distribution capacity in the US

Through its wholly-owned subsidiary AdvaGen Pharma, the company directly markets over 350 SKUs to 96 customers, including all three major US wholesalers that control 90% of distribution. Validus further extends branded sales capabilities, with distribution across 44 states and strong CNS prescriber relationships.

Cost-effective manufacturing

According to F&S, the company’s manufacturing facilities are based in India, where the cost of manufacturing is 30-40% lower than in the US. This enables the company to compete in developed markets while minimising cost. Further, it also utilised third-party manufacturing during periods when its facilities were highly utilised or were not equipped for specific types of manufacturing, allowing the company to meet demand and maintain supply.

Objectives of Rubicon Research Limited IPO

Repayment of loans
62.00%
The company intends to use ₹310 crore towards the payment/repayment of borrowings.
Inorganic growth and general corporate purposes
38.00%
IPO funds will cover unidentified acquisitions and general corporate purposes.

Compare

CompanyRevenue*3Y growthPATMarket capP/E ratioD/E ratio
This IPO₹1,284Cr80.65%₹134.36Cr₹7,987Cr54.990.51
This sector (avg.)₹1,331.47Cr0%₹193.4Cr₹10,914.84Cr60.870.43
₹52,578.44Cr---₹10,980.1Cr₹3,82,765.9Cr36.980.03
₹9,360Cr---₹2,191Cr₹1,60,635Cr64.600
₹11,516.09Cr---₹1,911.25Cr₹1,34,051.5Cr62.640.42

*Revenue for financial year 2024-25. Lower P/E and D/E ratios are generally preferred.

Rubicon Research IPO Contact Details

Company NameRubicon Research Limited

How to apply for Rubicon Research IPO?

  1. Step 1

    Log in to your Upstox account to access IPO investments. Next, select the current IPO section.

  2. Step 2

    Specify IPO details. Enter the number of lots and the price you wish to apply for.

  3. Step 3

    Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.

  4. Step 4

    Mandate Notification. Your UPI app will receive a mandate notification to block funds.

  5. Step 5

    Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.

Rubicon Research Limited IPO FAQs

Investors can apply for the Rubicon Research IPO through their Demat account via the stock exchange or through their broker.
The issue size of the Rubicon Research IPO is 1377 Cr.
Pre-applying for an IPO allows you to submit your application before the official subscription period begins.
The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.
Rubicon Research IPO will be open between 2025-10-09 and 2025-10-13.
Rubicon Research IPO allotment date is 2025-10-15. For Rubicon Research IPO allotment status check, you can visit the website of the registrar of the IPO.
For Rubicon Research IPO, the IPO registrar is MUFG Intime India Private Limited. You can check Rubicon Research IPO allotment status on the website of the registrar.
The shares are proposed to be listed on the BSE and NSE.
The Rubicon Research IPO shares will typically be credited to your demat account one working day before the IPO's listing date, provided your application is successfully allotted.
The Rubicon Research IPO lot size is 30 and minimum order quantity is 30.
Rubicon Research IPO has set the price band for its IPO at 485 per equity share with a face value of 1.